With Singulair Gone, It’s Test Time For Merck’s Post-LOE Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
With Singulair’s loss of exclusivity on Aug. 3, Merck’s bets on growth of its existing franchises and late-stage pipeline have come under scrutiny. Next up: Tredaptive Phase III data in early 2013.
You may also be interested in...
Patent Cliff Continues in 2014, But Not So Steeply
Most of big pharma has crossed to the other side of the patent cliff and put their biggest losses behind them in 2012 and 2013, but a few major blockbusters will face new generic competition this year, including Nexium, Copaxone, and Nasonex.
Is Merck Less Bullish on Biosimilars?
Of all the Big Pharma manufacturers, none seemed more optimistic about the commercial potential of biosimilars than Merck. But over the last several months, Merck shut down its BioVentures Group and skipped an FDA public meeting on the abbreviated approval pathway. Has Merck soured on biosimilars?
UPDATED: Zetia/Lipitor Combo’s Ongoing Clinical Equivalence Trials May Address FDA’s Data Request, Merck Says
FDA did not accept the company’s bioequivalence arguments supporting a fixed-dose combination of ezetimibe and atorvastatin. Merck believes new data that are expected to be available later this year may address the agency’s “complete response” letter.